The invention provides compounds of Formula (I), or pharmaceutically acceptable salts 5 thereof:

##STR00001##

The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

The present invention relates to methods of treatment of a disease or pathology of the central nervous system, an eating disorder, or substance use disorder, drug dependence/abuse/addiction and withdrawal therefrom comprising administering at least one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl amphetamine derivative to an individual in need thereof.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.

Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:

##STR00001##

Disclosed in the invention are a type of compounds having aldolase selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for inhibiting triglyceride and cholesterol synthesis, for reducing fatty acid synthesis, for preventing and/or treating obesity and type II diabetes, for preventing and/or treating tumor, for preventing and/or treating Parkinson's disease, for preventing and/or treating Alzheimer's disease or for prolonging the lifespan of mammals:

##STR00001##

The present invention relates generally to glutaminase inhibitors of Formula I, Formula II, or Formula III, as well as pharmaceutical compounds containing them and methods of their use.

Charged organic thermally activated delayed fluorescence (TADF) species are described. A light-emitting electrochemical cell (LEEC) includes the charged organic thermally activated delayed fluorescence (TADF) species and sufficient counter ions to balance the charge on the charged organic thermally activated delayed fluorescence species, as emitter material. Also disclosed are OLEDSs containing the TADF species.

Charged organic thermally activated delayed fluorescence (TADF) species are described. A light-emitting electrochemical cell (LEEC) includes the charged organic thermally activated delayed fluorescence (TADF) species and sufficient counter ions to balance the charge on the charged organic thermally activated delayed fluorescence species, as emitter material. Also disclosed are OLEDSs containing the TADF species.

There is provided novel agricultural chemicals, in particular herbicides. A ketone or oxime compound or a salt thereof of Formula (1):

##STR00001##

wherein B is a ring of any one of B-1, B-2, or B-3, Q is an oxygen atom, a sulfur atom, NOR.sup.7, etc., R.sup.6 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.7 is a hydrogen atom, C.sub.1-6 alkyl, etc., R.sup.8a, R.sup.8b, R.sup.9a, R.sup.9b, R.sup.10, R.sup.11, R.sup.12, R.sup.13, and R.sup.14 are each independently a hydrogen atom, C.sub.1-6 alkyl, etc., m is an integer of 1 or 2, n is an integer of 0, 1 or 2; and a herbicide including the compound or salt thereof.